Disclaimer: This page is intended for Healthcare Professionals and other relevant decision makers in United Kingdom (Great Britain) only.
Information about the BIMERVAX® Covid-19 Vaccine.
Marketing authorisation for United Kingdom (Great Britain) has been granted by the European Medicines Agency to be used for individuals 16 years of age and older.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.
More information
For any information about this medicine including product quality complaint, please contact our COVID-19 vaccine dedicated Contact Center:
Local number: +44 20 3148 4573
Mail: humanhealth.uk@hipra.com
Company information
17170 Amer (Girona)
Spain